Cocaine addiction is a major problem for which there is no approved pharmacotherapy. We have developed a vaccine to cocaine (dAd5GNE), based on the cocaine analog GNE linked to the capsid proteins of a serotype 5 adenovirus, designed to evoke anti-cocaine antibodies that sequester cocaine in the blood, preventing access to the CNS. To assess the efficacy of dAd5GNE in a large animal model, positron emission tomography (PET) and the radiotracer [
INTRODUCTION
With an estimated 1.4 million cocaine users in the United States, cocaine addiction is a major problem for which there are no FDA-approved therapies (Dept. of Health and Human Services 2011). The cocaine 'high' is initiated by cocaine-mediated accumulation of dopamine in the ventral striatum, caudate, and putamen of the basal ganglia (DiChiara et al 2004; Koob and Volkow 2010; Volkow et al 1997a; Volkow et al 1997b) . Dopamine is synthesized in the presynaptic neuron and is stored in intracellular vesicles (Anderson et al 1998; Koob and Volkow 2010) . Following release of dopamine from the presynaptic neuron into the synaptic cleft, dopamine binds to dopamine receptors on the postsynaptic neuron, and to the dopamine transporter (DAT) for reuptake by the presynaptic neuron (Haile et al 2012b; Howell and Kimmel 2008; Kahlig and Galli 2003) . Cocaine binds to the DAT and inhibits dopamine reuptake, resulting in dopamine accumulation in the synaptic cleft of the transmitting neuron. This prolongs and amplifies postsynaptic dopamine signaling at the dopamine receptors, resulting in rewarding effects (Haile et al 2012b; Nader and Czoty 2005; Volkow et al 1997b) . In humans, at least 47% of the DAT must be occupied by cocaine to evoke the perceived rewarding effects or 'high' (Volkow et al 1997a) .
The strategy of an anti-cocaine vaccine is to prevent cocaine access to the brain, and hence, to prevent the ability of cocaine to reach the DAT in the caudate and the putamen. Two approaches, passive and active immunization, have been used to develop anti-cocaine immunotherapies. The small size and lipid solubility of addictive drugs represent a great challenge for therapies that seek to block the rapid passage across the blood-brain barrier and ultimately restrict access to cognate receptors. A therapeutic approach that engages the addictive drug before crossing the blood-brain barrier, before it stimulates the drug reinforcement and reward pathways, would have the advantage of blocking the effect by specifically targeting the drug itself and not impacting normal downstream CNS signaling pathways.
Passive immunotherapies for the treatment of cocaine addiction make use of monoclonal antibodies directed toward the cocaine molecule (Brimijoin et al 2013; Carroll et al 2012; Norman et al 2007; Ramakrishnan et al 2012) . Current strategies, at this time tested only in experimental animals, either administer large amounts of purified anticocaine monoclonal antibodies (to use as an antidote to treat overdose) (Treweek and Janda 2012) or for longer duration treatment, gene therapy to the liver of the gene sequence of the anti-cocaine monoclonal antibody to induce persistent expression of the monoclonal antibody .
Active vaccines against cocaine are comprised of a cocaine analog coupled to an immunogenic protein.
The TA-CD vaccine, succinylated norcocaine linked to cholera toxin B subunit, was effective in experimental animals, and in humans demonstrated some efficacy for those individuals in whom it evoked high anti-cocaine titers (Haney et al 2010; Martell et al 2009; Shen et al 2012) . With the goal of blocking access of cocaine to the CNS to prevent DAT occupancy levels that induce cocaine's psychotropic effects, we have developed an anti-cocaine vaccine (dAd5GNE) based on a cocaine analog covalently coupled to the capsid proteins of a disrupted serotype 5 human adenovirus Wee et al 2012) . Studies in mice and rats have shown that dAd5GNE prevents cocaine-induced hyperactivity and addiction-related behavior in these species (Koob et al 2011; Hicks et al 2011; Wee et al 2012) .
In general, vaccine studies in rodents are not sufficient to predict efficacy in humans, whereas nonhuman primates (NHP), due to similar physiology and genetics, are considered informative (Herodin et al 2005) . For the cocaine vaccine, efficacy is measured by a phenotype that depends upon cocaine-DAT binding at levels above a threshold. Because rodents and primates metabolize cocaine and the DAT radiotracers differently, measures of these compounds in the NHP brain better model humans and thus are more relevant for translation to clinical study (Lindsey et al 2004; Nader and Czoty 2008; Seki et al 2010; Shetty et al 2007; Volkow et al 1997a; Ward and Smith 2004; Wilcox et al 2002) . Furthermore, the large brain of the NHP imaged with positron emission tomography (PET) technology also provides the high resolution for quantitative imaging of the putamen and caudate, areas of the CNS directly relevant to cocaine addiction (Halldin et al 2003; Volkow et al 1997a) .
The goal of the present study was to use PET imaging to directly assess the capacity of dAd5GNE to block cocaine access to the DAT transporter in the brain of NHP and to determine whether this blockade persists with repeated cocaine administrations over time. To accomplish this, we used the PET imaging radiotracer [ 11 C]PE2I, a high-affinity ligand specific for DAT (Dolle et al 2000; Emond et al 2008; Halldin et al 2003) , to evaluate the efficacy of dAd5GNE to repeatedly prevent cocaine from crossing the blood-brain barrier and block DAT function of NHP.
METHODS dAd5GNE Vaccine
The source of the adenovirus capsid proteins for the dAd5GNE vaccine was Ad5bgal, a recombinant E1a À , partial E1b
À , and the E3 À serotype 5 Ad vector with b-galactosidase in the expression cassette Rosenfeld et al 1992; Wee et al 2012) . The Ad5bgal vector was disrupted in 0.5% sodium dodecyl sulfate at 56 1C for 45 s. The cocaine hapten GNE (0.3 mg) was activated overnight at 4 1C after the addition of 7.2 ml charging solution (2.4 mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride and 2 mg of N-hydroxysulfosuccinimide in 4 ml H 2 O and 40 ml dimethylformamide) Wee et al 2012) . The conjugation of the disrupted Ad5bgal vector (200 mg) with the charged GNE (67 mg; 300 : 1 GNE to Ad capsomere molar ratio) was carried out by overnight incubation at 4 1C in phosphatebuffered saline (PBS, pH 7.4). The amount of Ad vector proteins was quantified using the bicinchoninic acid assay (Pierce Biotechnology, Rockford, IL).
Study Design
The study included five female Rhesus macaques (Macaca mulatta), age 5.1 ± 0.6 years. Four were vaccinated with the dAd5GNE vaccine and one was used as a non-vaccinated control. After an initial PET scan (see below), four animals were vaccinated by intramuscular injection to the quadriceps with 100 mg of dAd5GNE in a 0.5-ml volume, formulated in 20% Adjuplex (Advanced BioAdjuvants, Omaha, NE), an adjuvant made with a purified lecithin and carbomer homopolymer. The vaccine was administered at 0, 3, and 5 weeks for all four animals, and subsequently, as required to maintain high titer for PET scan. Before and multiple times after initial vaccine administration, venous blood was collected to assess anti-cocaine antibodies. The blood was allowed to clot (30 min, 23 1C) , and centrifuged at 10 000 g for 20 min. The isolated serum was stored at À 20 1C. PET scans with [ 11 C]PE2I were carried out before and 2-5 times after the initial vaccination over a period of 12 months (see Supplementary Table S1 ).
dAd5GNE Evoked Anti-Cocaine Antibody Titers
To quantify anti-cocaine titers following vaccination, wells of flat-bottomed 96-well EIA/RIA plates (Corning, New York, NY) were coated with 100 ml of 1 mg/ml of the cocaine hapten GNE Wee et al 2012) conjugated to bovine serum albumin (BSA, ratio of 1 : 2) in bicarbonate buffer, pH 9.4 overnight at 4 1C (the conjugation was as described above but BSA was substituted for dAd5). The plates were washed with 0.05% Tween 20 in PBS (PBS-Tween) and blocked with 5% dry milk in PBS for 30 min, 23 1C. Twofold serial dilutions of serum were added to each well and incubated for 90 min, 23 1C. The plates were washed four times with PBS-Tween. Diluted horseradish peroxidase-conjugated goat anti-monkey IgG (Santa Cruz Biotechnology, Santa Cruz, CA), 100 ml of 1 : 2000 in 1% dry milk in PBS, was added to each well and incubated for 90 min, 23 1C. The plates were washed four times. Peroxidase substrate (100 ml/well; Bio-Rad, Hercules, CA) was added and incubated for 15 min, 23 1C. The peroxidase reaction was stopped with addition of 2% oxalic acid (100 ml/well). Absorbance was measured at 415 nm. Anticocaine antibody titers were calculated by interpolation of the log(OD) À log(dilution) with a cutoff value equal to twofold the absorbance of background.
Synthesis of [
11 C]PE2I C-labeled methyl ester of trifluoromethansulfonic acid ( 11 C-methyl triflate) at 50 1C for 5 min (Dolle et al 2000) . Synthesis was initiated with 0.5 mg precursor (PE2I acid) dissolved in 500 ml acetone and 3 ml 2 M sodium hydroxide added B3 min before the release of 11 C-methyl triflate. Upon completion of the 11 C-methyl triflate collection, the reaction mixture was heated for 5 min at 50 1C followed by reaction quenching with 1 ml mobile phase. The reaction mixture was loaded onto a 7.8 mm Â 300 mm Waters' mBondapak C-18 column (Waters Co, Milford, MA) and column eluted with 0.01 M phosphoric acid: acetonitrile gradient at 6 ml/min. The fraction containing [ 11 C]PE2I was collected into 50 ml water. [
11 C]PE2I was trapped on Waters' C-18 sep-pak cartridge (Waters Co) and subsequently formulated with 7% ethanolic saline solution followed by sterile filtration using a 0.22-mm membrane filter. The synthesis was accomplished in 40.8±2.7 min. The radiochemical yield was 40.1±5.8% (decay corrected) with the chemical and radiochemical purities in excess of 90%. The average specific activity (SA) of [ 11 C]PE2I at the end of synthesis was 13.8±6.1 Ci/mmol. In each study, there was no significant difference in the SA of [ 11 C]PE2I according to time of administration (first administration, 9.1±4.3 vs second administration, 7.9 ± 3.6 Ci/mmol, P ¼ 0.3).
PET and MRI Imaging
PET imaging studies were performed following intravenous administration of [ 11 C]PE2I (5 mCi). At each session, PET imaging was carried out before and after cocaine challenge (1 mg/kg). Cocaine was injected over a period of 30 s via an intravenous port located either in the saphenous vein (leg) or the cephalic vein (arm). During the vaccination regimen, PET studies were repeated for each animal 2-5 times over a period of 12 months (see Supplementary Table S1 ).
PET scans were performed using a microPET scanner (Siemens/CTI Concorde Focus 220). Data was acquired in list mode format for 90 min. Following acquisition, a 57 Co point source was used for attenuation correction. Histograms were created consisting of 28 time frames; 4 of 15 s, 4 of 30 s, 7 of 60 s, 10 of 300 s, and 3 of 600 s. Images were reconstructed using ordered subset expectation maximization two-dimensional. Each series was composed of 95 slices (field-of-view) with 128 Â 128 matrix yielding a 1.9 mm Â 1.9 mm Â 0.8 mm voxel size.
Magnetic resonance imaging (MRI) was performed on each NHP using a 3.0-Tesla Siemens TIM Trio scanner (Siemens, Malvern, PA) with a single loop surface coil placed on the head. An axial 3D T 2 -weighted spin-echo sequence used a 18 cm Â 18 cm field-of-view, 1.0 mm slice thickness, 72 slices, 256 Â 256 in-plane matrix, and an echo train length of 259, yielding 0.7 mm Â 0.7 mm Â 1.0 mm voxel resolution. A 3200 ms pulse sequence repetition time and an effective echo time of 454 ms was used with four averages, resulting in a scan time of 6 min. To identify CNS structures, PET scans were co-registered to their corresponding MRI scans using FSL/Flirt (FMRIB's linear image registration tool, version 4.0, FMRIB Image Analysis Group, Oxford, UK). The cerebellum was identified as a reference region (Ciliax et al 1999; Seki et al 2010) . Anatomical localization of the regions of interest, caudate and putamen, and the reference region were identified on coronal MRI images and used for PET quantification (see coronal images for illustration of tracing of the regions of interest, Supplementary Figure S1 ).
Quantitative Analysis
To quantify the DAT binding potential (BP) from in vivo PET studies, the specific binding of the radioligand [ 11 C]PE2I to the target receptor (DAT) was measured using the four-parameter reference tissue model (Hume et al 1992; Lammertsma et al 1996) . This model requires two time-activity curves: one from DAT receptor-rich region (in this study, the caudate and putamen) and one from a reference region devoid of receptors (in this study, the cerebellum). The model assumes that the distribution volume of the non-displaceable compartment (free and nonspecifically bound tracer) is the same for the tissue of interest (caudate and putamen) and the reference tissue (cerebellum). Using the model, the ratio at equilibrium of specifically bound radioligand to non-displaceable radioligand (sum of free and nonspecifically bound radioligand in tissue) can be determined, and is defined as the BP ND (Innis et al 2007) . The [ 11 C]PE2I radioligand was administered at a tracer dose (see above) to avoid perturbation of the receptor-ligand system (Innis et al 2007) . Quantification was done using PMod software (PMOD version 3.1; PMOD Technologies, Zurich, Switzerland).
To determine the cocaine occupancy, two consecutive [
11 C]PE2I PET scans in the absence or presence of cocaine were performed. In the first scan only [ 11 C]PE2I was administered, whereas in the second scan cocaine (1.0 mg/kg) was administered and immediately followed by 
Cocaine vaccine prevents cocaine CNS binding A Maoz et al Statistics Data (antibody titer, BP, and cocaine occupancy) are expressed as mean ± SE, specific activity is expressed as mean ± SD. A paired repeated measures analysis of variance accounting for within-subject variability was performed before and after vaccination. Additionally, comparisons between vaccinated and non-vaccinated groups were conducted by unpaired two-sample t-test (Table 1 ). The nonvaccinated group included all PET studies from experimental NHP before vaccination and the one non-vaccinated control, and the PET studies from vaccinated animals were categorized into two groups: (1) all NHP after vaccination and (2) those only with titers 44 Â 10 5 . The Pearson correlation was used to calculate the correlation coefficient between anti-cocaine antibody titer and cocaine occupancy (%). PET studies were also sub-categorized according to titer; no titers, titers o4 Â 10 5 , and titers 44 Â 10 5 , and comparisons between groups were conducted by unpaired two-sample t-test. Statistical analysis was done using Matlab (Mathworks, Natick, MA).
RESULTS
Administration of the dAd5GNE vaccine evoked high titers of anti-cocaine antibody by 7 weeks after initial immunization (Figure 1a-d) . Repeat administration of dA5GNE boosted the anti-cocaine antibody titer during the 50-week study. No anti-cocaine antibody titers were seen in the control NHP. On the average, after the prime and second boost for the four NHP, the titers were 4.9±0.4 Â 10 5 . As we observed in mice and rats Wee et al 2012) , maintenance of high titer required re-administration of the vaccine.
To evaluate the capacity for cocaine occupancy of DAT, the affinity of the [ 11 C]PE2I radiotracer for DAT was measured by determination of the BP in the absence of cocaine according to reference tissue modeling as described in Methods (Sasaki et al 2012; Seki et al 2010) . PET imaging of the brain of naive NHPs (both control and NHPs before vaccination) showed that [ 11 C]PE2I bound to the highdensity DAT region of the striatum, with a high BP in the caudate (8.3 ± 0.3, n ¼ 8) and the putamen (8.7 ± 0.4, n ¼ 8; Figure 2a left images, Figure 2b -e top left images, and Table 1 ). Vaccinated NHPs had a similarly high BP of [ 11 C]PE2I to the DAT in the caudate (9.1±0.7, n ¼ 12) and the putamen (9.1 ± 0.7, n ¼ 12; Figure 2b -e, bottom left images and Table 1 ; P ¼ 0.3). There was no difference in BPs in the absence of cocaine between vaccinated and Vaccinated 9.1 ± 0.7 9.1 ± 0.7 6.3 ± 0.5 6.3 ± 0.5 2.8 ± 0.6 2.8 ± 0.7 28.3 ± 4.9 27.0 ± 6.1 27.6 ± 5.4
Titers 44 Â 10 5 8.1 ± 0.7 8.1 ± 0.8 6.7 ± 0.6 6.9 ± 0.6 1.5 ± 0.2 1.2 ± 0.3 17.5 ± 2.5 13.7 ± 3.5 15.6 ± 3.0
Non-vaccinated vs vaccinated P-value 0.21 0.35 o8.4 Â 10 À 5 o1.7 Â 10 À 4 o5.6 Â 10 À 3 o6.8 Â 10 À 3 o7.1 Â 10 À 5 o2.0 Â 10 11 C]PE2I BPs in the caudate (6.7 ± 0.6, n ¼ 12, Table 1 ) and putamen (6.9±0.6, n ¼ 12, Table 1 (Figure 3b vs Figure 3d ). There was variability from animal to animal. As an example, in NHP #3 at 21 weeks post vaccination, there was only a small decrease in [
11 C]PE2I binding following administration of cocaine, resulting in the calculated cocaine occupancy of only 22.5% (Figure 3c vs Figure 3d ); in contrast, in NHP #3 at 0 weeks, there was a large displacement of [ 11 C]PE2I binding after cocaine administration, with a cocaine occupancy of 67.0% (Figure 3a and b) . The vaccinated animal showed reduced cocaine access to the DAT during the 90-min time course of the PET scan, the longest time point evaluated.
Comparison of studies before and after vaccination (pairwise repeated measures analysis) demonstrated a reduction in cocaine occupancy (Po0.02, F ¼ 28.32). Cocaine occupancy in both the caudate and putamen correlated inversely with anti-cocaine antibody titers (Figure 4) . Relevant to the cocaine occupancy of 47%, 
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A Maoz et al which represents the threshold associated with the subjective 'high' (Volkow et al 1997a) , the pre-vaccinated NHP and the non-vaccinated control animal demonstrated cocaine occupancies at or above 47% following cocaine administration. However, vaccinated NHP with antibody titers 44 Â 10 5 invariably had cocaine occupancy o20%, significantly below 47% (Figure 4) , indicating the capacity of dAd5GNE vaccine to limit cocaine occupancy below the threshold level. In non-vaccinated NHP, cocaine occupancy was 62.5 ± 4.2%. Post vaccination, when the anti-cocaine antibody titers were o4 Â 10 5 , the reduction in cocaine occupancy, although significant (Po0.03), was just 10%. In contrast, in NHP with anti-cocaine antibody titers X4 Â 10 5 , the cocaine occupancy was only 15.6±2.5%; this is a fourfold reduction in average cocaine occupancy (Po10 À 6 ; Figure 4d ).
DISCUSSION
The addictive properties of cocaine result from the cocainemediated blockade of the DAT in the caudate and putamen, allowing dopamine to accumulate in the synaptic clefts (Haile et al 2012b; Howell and Kimmel 2008; Kahlig and Galli 2003; Koob and Volkow 2010) . In humans, the perceived rewarding effect or 'high' from cocaine occurs when there is 447% DAT occupancy by cocaine (Volkow et al 1997a) . Thus, for an anti-cocaine vaccine to be successful, it must be able to prevent cocaine access to DAT below this threshold. Using PET imaging with [ 11 C]PE2I DATspecific tracer, the data demonstrates that the dAd5GNE vaccine can effectively reduce cocaine DAT occupancy below this threshold to levels of o20% in NHP with high titers consistent with the conclusion that dAd5GNE could be an effective vaccine for cocaine addiction.
Experimental animal and human studies using PET to evaluate cocaine occupancy of the DAT have substantiated the role of dopamine and cocaine DAT occupancy in the reward and addiction pathway circuitry of the basal ganglia (Gould et al 2012; Hanlon and Canterberry 2012; Koob and Kreek 2007; Koob and Volkow 2010; Votaw et al 2002) . The PET imaging radiotracer [ 11 C]PE2I, which has high affinity and specificity for DAT, has optimized the assessment of cocaine binding to DAT (Halldin et al 2003; Emond et al 2008) . The current study provides a novel approach of using this tracer as a tool to measure the efficacy of anti-cocaine therapy to reduce distribution of cocaine to the DAT, a technology that could be applied to human trials of anticocaine vaccine efficacy.
To date, most therapies in development to treat cocaine addiction have focused on a receptor agonist or antagonist mechanism to reduce the sensitivity to the pharmacological action of cocaine (Howell and Kimmel 2008; Jupp and Lawrence 2010; Kalivas 2007; Moeller et al 2012; Volkow et al 2009). Several drugs (eg, vigabatrin, tiagabine, modafinil, and disulfiram) showed promise in experimental animal studies, but clinical trials with these drugs have been inconclusive (Goudriaan et al 2013; Haile et al 2012a; Haile et al 2012b; National Institute on Drug Abuse 2010; Shorter and Kosten 2011) . Because these pharmacotherapies attempt to reduce sensitivity in the brain to the pharmacological effect of cocaine, they mostly target pathways associated with cocaine addiction. Consequently, they may have downstream or secondary effects from the site of drug action, and may block other dopaminergic pathways (Best et al 2009; Zheng and Zhan 2012) . In contrast, immunotherapies to treat cocaine addiction in the periphery are highly specific for the cocaine moiety and do not act on the brain signaling pathways, do not alter normal brain function and are thus less likely to evoke adverse effects (Czoty and Roberts 2012; Shorter and Kosten 2011; Zheng and Zhan 2012) .
PET results for the high titer anti-cocaine dAd5GNE-evoked immunity in the NHP demonstrated that the vaccine effectively sequestered administered cocaine in the blood and that repeat vaccine administrations were required to maintain an effective anti-cocaine antibody titer (44 Â 10 5 ). After the initial three administrations of the vaccine, each animal received vaccine booster shots to assure high anti-cocaine titers before PET imaging. The intent was to demonstrate proof-of-principle for vaccine efficacy. The range of antibody titers allowed determination of a threshold for efficacy in the context of a relatively high dosage of cocaine (1 mg/kg intravenous), higher than that administered in human studies (0.3-0.6 mg/kg intravenous; Haney et al 2010; Volkow et al 1997a) . Interestingly, the best results with the TA-CD anti-cocaine vaccine (currently in clinical trials) were achieved only in individuals with the highest titers (Haney et al 2010) . Here we found that titers above a threshold of 4 Â 10 5 were effective at preventing cocaine access to the putamen and caudate DATs. The dAD5GNE vaccine demonstrated efficacy with evoked titers above threshold in three of the four vaccinated NHP. As with most vaccines in which the breadth of coverage is typically o100%, a diverse genetic background is the likely factor for the low anti-cocaine titer (B2 Â 10 5 ) in one NHP in this study. Although not tested, an increase in vaccine dose may improve breadth of high-titer response. Rigorous evaluation of vaccine coverage would require a larger experimental group.
In the context that our laboratory and others have demonstrated excellent clinical safety profiles with infectious Ad vectors (Harvey et al 1999) , it is expected that the use of a disrupted adenovirus will be relatively benign with respect to safety, particularly because dAd5GNE also lacks the ability to express any viral genes. While it is important to note that animals in this study received multiple dAd5GNE vaccinations and did not demonstrate systemic, site-of-injection, or behavioral adverse effects, extensive and formal evaluation of toxicology parameters will be necessary for vaccine development for human testing.
In this study, we show a novel approach using PET imaging to evaluate the efficacy of an anti-cocaine vaccine, dAd5GNE. This vaccine is based on the highly immunogenic capsid proteins of the human serotype 5 adenovirus, the stable cocaine hapten GNE, and the Adjuplex adjuvant. The data in the present study demonstrate that, in a NHP model, repetitive administration of the vaccine maintains high levels of anti-cocaine titers, sufficient to prevent systemically administered cocaine from binding to the DAT in the putamen and caudate at levels required to generate rewarding effects of cocaine in humans (Volkow et al 1997a) .
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